Financial News
Latest News about MRK
Recent news which mentions MRK
Personalized Treatment And Immunotherapy Are Pharma's Newest Weapons Against Cancer
October 10, 2024
From Benzinga
Jim Cramer Says He's Buying 'Some Target,' But Dismisses SoundHound AI As 'Meme Stock'
October 09, 2024
From Benzinga
Merck's Mumps Vaccine Controversy: Class-Action Lawsuit Alleges Anticompetitive Behavior, Court Shields From Liability
October 08, 2024
From Benzinga
Merck Touts Phase 3 Success For $20B Cancer Drug Keytruda In Untreated Head And Neck Cancer Patients
October 08, 2024
Tickers
MRK
From Benzinga
10 Health Care Stocks Whale Activity In Today's Session
October 07, 2024
From Benzinga
2 Soaring Stocks That Could Climb Another 112% and 120%, According to Wall Street Analysts
October 07, 2024
From Motley Fool
Is It Time to Buy September's Worst-Performing Dow Jones Stocks?
October 05, 2024
From Motley Fool
Novo Nordisk/AstraZeneca's Manufacturing Partner Thermo Fisher Questioned Over Manufacturing Lapses
October 04, 2024
From Benzinga
Could Summit Therapeutics Become the Next Merck?
October 04, 2024
From Motley Fool
Exploring The Competitive Space: Merck & Co Versus Industry Peers In Pharmaceuticals
October 03, 2024
From Benzinga
The Covid Era Tech Promises To Reinvent Cancer Treatment
October 01, 2024
From Benzinga
2 High-Potential Growth Stocks You Shouldn't Overlook
September 29, 2024
From Motley Fool
Evaxion Biotech Partners With Merck To Expand Vaccine Development
September 26, 2024
From Benzinga
FDA Casts Doubt On Use Of Merck, Bristol Myers' PD-1 Cancer Drugs For Certain Type Of Gastric Cancer Patients
September 25, 2024
From Benzinga
Eli Lilly Touts Results Of EU-Approved Dermatitis Treatment, Shows Sustained Disease Control For Up To Three Years
September 25, 2024
From Benzinga
Merck's Experimental Favezelimab/Keytruda Combo Fails In Late-Stage Colorectal Cancer Study
September 25, 2024
From Benzinga
Pfizer Advances On Its Cancer Journey
September 20, 2024
From Benzinga
Is It Too Late to Buy ServiceNow Stock?
September 20, 2024
From Motley Fool
Merck's Keytruda Secures First FDA-Approval For Rare Form Aggressive Cancer
September 18, 2024
From Benzinga
Behind the Scenes of Merck & Co's Latest Options Trends
September 18, 2024
Tickers
MRK
From Benzinga
This Company Generates No Revenue and Its Market Cap Is Over $20 Billion. Here's Why That Valuation May Not Be All That Ridiculous.
September 18, 2024
From Motley Fool
Prediction: These Could Be the Best-Performing Biotech Stocks Through 2030
September 18, 2024
From Motley Fool
Competitor Analysis: Evaluating Merck & Co And Competitors In Pharmaceuticals Industry
September 17, 2024
From Benzinga
Merck/Daiichi Sankyo Partnered Lung Cancer Candidate Meets Primary Goal In Late-Stage Study
September 17, 2024
From Benzinga
A Closer Look at 8 Analyst Recommendations For Merck & Co
September 16, 2024
Tickers
MRK
From Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
